The Effect of an Acute Increase in Plasma IL-6 on Glucose Tolerance When a Meal is Administered Intraduodenally
NCT03660332 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6
Last updated 2024-02-26
Summary
The aim of the study is to investigate and clarify whether the effect of IL-6 on glucose tolerance and insulin secretion are secondary to the changes in gastric emptying.
The literature provides no information regarding a role for interleukin-6 (IL-6) in the regulation of beta cell function (glucose or meal-stimulated insulin secretion) in humans. Previous studies infusing IL-6 into humans have primarily focused on insulin action and the effects on peripheral insulin sensitivity whereas a potential effect on insulin secretion has been neglected.
We have demonstrated that an acute increase in IL-6, obtained by a single bolus of IL-6, potentiated glucose-induced insulin secretion in a glucagon-like peptide-1 (GLP-1) dependent manner in mice1. In mice, IL-6 enhanced insulin secretion in a dose- and glucose-dependent manner, along with increasing concentrations of GLP-1. Interleukin-6 had no effect on insulin secretion in GLP-1 receptor knock-out mice or in mice treated with the GLP-1 receptor antagonist. Thus, in mice, GLP-1 has proven an essential mediator of IL-6 actions on beta cell function.
Importantly, a single bolus of IL-6 also significantly increased glucose-stimulated insulin secretion in several mouse models of obesity and diabetes (diet-induced obesity, the ob/ob and the db/db mouse).
Own data show that an infusion of IL-6 causes a significant delay in the rate of gastric emptying (GE) after a mixed meal in healthy young men. Data showed that this delay in GE is associated with much improved glucose tolerance and insulin secretion (unpublished data).
In the present study we wish to investigate whether the beneficial effects of IL-6 on postprandial glucose tolerance and insulin secretion are dependent on a delay in gastric emptying. We will bypass the ventricle and infuse a mixed meal directly into the duodenum of healthy young men.
This study has the potential to show that the known effect of IL-6 on postprandial glucose tolerance is dependent on a delayed GE.
Conditions
- Postprandial Glucose Homeostasis
Interventions
- PROCEDURE
-
Infusion of a liquid meal intraduodenally
Infusion of IL-6/NaCL before a liquid meal intraduodenally
Sponsors & Collaborators
-
Rigshospitalet, Denmark
lead OTHER
Principal Investigators
-
Bente K Pedersen, Professor · CFAS, Rigshospitalet
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 35 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-01-01
- Primary Completion
- 2017-04-01
- Completion
- 2017-04-01
Countries
- Denmark
Study Locations
More Related Trials
-
Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion
NCT03223129 ·Status: COMPLETED ·Phase: NA
-
Effect of Bile Acids on GLP-1 Secretion
NCT01666223 ·Status: COMPLETED ·Phase: NA
-
Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis
NCT06721910 ·Status: COMPLETED ·Phase: NA
-
Colonic Glucose vs. Saline Infusion
NCT05302206 ·Status: UNKNOWN ·Phase: NA
-
Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176760 ·Status: UNKNOWN ·Phase: NA
-
Incretin Physiology Associated With Steroid Hormone Treatment
NCT00713440 ·Status: COMPLETED ·Phase: NA
-
Physiology of GIP(1-30)NH2 in Humans
NCT04792762 ·Status: COMPLETED ·Phase: NA
-
Study of Postprandial Incretin Response in Women With Gestational Diabetes
NCT01274052 ·Status: COMPLETED
-
The Glucose-Independent Effects of Exogenous Glucagon on Insulin Secretion and Cognitive Function in Healthy Subjects
NCT06685146 ·Status: COMPLETED ·Phase: NA
-
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?
NCT03954873 ·Status: COMPLETED ·Phase: NA
-
The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans
NCT00273000 ·Status: UNKNOWN ·Phase: NA
-
Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis
NCT04907721 ·Status: COMPLETED ·Phase: NA
-
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NCT00655603 ·Status: UNKNOWN ·Phase: NA
-
Intraileal Glucose vs. Saline Infusion on Hormone Secretion and Glycemic Excursions
NCT05030376 ·Status: COMPLETED ·Phase: NA
-
Assessment of Intranasal Glucagon on Endogenous Glucose Production
NCT02740829 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)
NCT04064203 ·Status: COMPLETED ·Phase: NA
-
Near Normalisation of BG Improves the Potentiating Effect of GLP-1
NCT00612625 ·Status: COMPLETED ·Phase: NA
-
Hepatic Metabolic Changes in Response to Glucagon Infusion
NCT03526445 ·Status: COMPLETED ·Phase: NA
-
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
NCT00862589 ·Status: COMPLETED ·Phase: NA
-
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
NCT02792400 ·Status: COMPLETED ·Phase: NA
-
Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176890 ·Status: UNKNOWN ·Phase: NA
-
Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion
NCT01176708 ·Status: UNKNOWN ·Phase: NA
-
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon
NCT01155206 ·Status: COMPLETED ·Phase: PHASE4
-
Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 Diabetes
NCT03044860 ·Status: COMPLETED ·Phase: NA
-
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT00732602 ·Status: COMPLETED ·Phase: NA